GlassScriptPhysician profile
Shanna Kulick
NPI 1578233102
$4,178.25
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $103 · 2022: $1,889 · 2023: $2,186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,185.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $715.22 | 2022-2023 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $614.24 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $472.79 | 2021-2023 | Breztri, Farxiga |
| Lilly USA, LLC | $393.44 | 2022-2023 | Emgality, Jardiance, Mounjaro |
| Amgen INC. | $344.76 | 2022-2023 | Prolia, Evenity, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $281.61 | 2022-2023 | Xifaxan |
| Pfizer INC. | $258.39 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $185.06 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $171.72 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.78 | 2022-2023 | Stiolto Respimat, Synjardy, Jardiance |
| Merck Sharp & Dohme LLC | $121.49 | 2021-2023 | Belsomra |
| Seagen INC. | $79.99 | 2022 | |
| Inspire Medical Systems, INC. | $73.65 | 2023 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $62.07 | 2022-2023 | Eliquis |
| Paratek Pharmaceuticals, INC. | $60.36 | 2022-2023 | Nuzyra |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $35.82 | 2023 | Austedo |
| Novartis Pharmaceuticals Corporation | $34.56 | 2023 | |
| Sumitomo Pharma America, INC. | $23.54 | 2023 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $18.85 | 2023 | Keveyis |
| Janssen Biotech, INC. | $17.65 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.50 | 2021 | |
| Radius Health, INC. | $16.03 | 2023 | Tymlos |
| Actelion Pharmaceuticals US, INC. | $14.63 | 2023 | Uptravi, Opsumit |
| Glaxosmithkline, LLC. | $13.15 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $12.02 | 2022 | |
| Medtronic, INC. | $11.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shanna Kulick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.